VIDEO: Highlights in molecularly targeted therapy for MDS, AML from ASCO
Click Here to Manage Email Alerts
CHICAGO — David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, talked about two presentations on molecular targeted therapy from the ASCO Annual Meeting.
In a video interview, Sallman discussed data on the IRAK4 inhibitor emavusertib (CA-4948) in high-risk myelodysplastic syndrome and acute myeloid leukemia. He also talked about a trial looking at magrolimab plus azacitidine in TP53-mutant AML, which revealed median survival nearly double to what is seen with hypomethylating agent venetoclax-based combinations.
“I think what’s important — although we separate this disease from AML — is that MDS [with] excess blasts and AML can often be homogeneous, I would argue, for patients [with TP53 mutations] is basically uniform,” he said. “I think [this] argues that we need to be thinking more about these two diseases as one, particularly in the setting of TP53 mutation.”
Collapse
Daver NG, et al. Abstract 7020. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Garcia-Manero G, et al. Abstract 7016. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Click Here to Manage Email Alerts